



ALEMBIC LIMITED

Regd. Office: Alembic Road, Vadodara 390 003

UNAUDITED FINANCIAL RESULTS

FOR THE QUARTER ENDED 30TH JUNE, 2010

(Rs. In Lacs)


CONSOLIDATED RESULTS			Particulars	STANDALONE		
Quarter Ended on 30 th June 2010	Quarter Ended on 30 th June 2009	Previous Accounting year ended on 31st March 2010		Quarter Ended on 30 th June 2010	Quarter Ended on 30 th June 2009	Previous Accounting year ended on 31st March 2010
(Reviewed)	(Reviewed)	(Audited)		(Reviewed)	(Reviewed)	(Audited)
18214	15852	70360	1 (a) Net Sales / Income from Operations	18214	15852	70360
10065	13397	44509	Domestic	7989	7296	32846
28279	29249	114869	Exports	26203	23148	103206
372	185	1054	Total	372	185	1054
27907	29064	113815	Less : Excise Duty	25831	22963	102152
75	44	262	Net Sales / Income from Operations	75	44	262
			(b) Other Operating Income			
27982	29108	114077	Total Income	25906	23007	102414
-595	956	221	2 Expenditure	-595	956	221
10728	6162	35051	(a) Decrease/(increase) in stock in trade and work in progress	10728	6162	35051
4546	8377	21265	(b) Consumption of Raw Materials & Packing Materials	2742	3540	11737
3503	3284	14547	(c) Purchase of traded goods	3503	3284	14547
980	923	4327	(d) Employees' Cost	980	923	4327
39	62	565	(e) Research and Development Expense	39	62	565
5947	6293	26581	(f) Excise Duty	6006	6252	26472
25148	26057	102557	(g) Other Expenditure	23403	21179	92920
2834	3051	11520	Total	2503	1828	9494
61	25	168	3 Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items	61	25	168
2895	3076	11688	4 Other Income	2564	1853	9662
1103	1042	4302	5 Profit/(Loss) before Interest, Depreciation, & Exceptional Items	1103	1042	4302
441	808	3005	6 Depreciation	441	808	3005
1351	1226	4381	7 Interest (Net)	1020	3	2355
1351	1226	4381	8 Profit/(Loss) after Interest but before & Exceptional Items	1020	3	2355
1351	1226	4381	9 Profit / (Loss) before Exceptional Items	1020	3	2355
0	-	13	10 Exceptional Items	0	-	13
189	1	516	11 Net Profit / (Loss) from Ordinary Activities before Tax	189	1	376
15	-	-102	12 Tax Expense	15	-	-102
-1	-	-	Less : Provision for Wealth Tax	-1	-	-
1148	1225	3954	Less : Provision for Current Tax	817	2	2068
2670	2729	2670	Less/(Add) : Provision for Deferred Tax Liability/(Assets)	2670	2729	2670
-	-	31142	Add : Provision of Income Tax of earlier years written back (Net)	-	-	28903
-	-	1542	13 Net Profit / (Loss) from Ordinary Activities after Tax	-	-	1542
0.86	0.89	2.93	14 Paid up Equity Share Capital	0.61	-	1.53
-	-	0.77	(Face value of share Rs 2/-)	-	-	0.71
-	-	1.72	15 Reserves excluding Revaluation Reserve	-	-	1.41
-	-	4.40	16 Debenture Redemption Reserve	-	-	3.61
48762909	51705496	48762909	17 Earnings Per Share (EPS)	48762909	51705496	48762909
36.52	37.89	36.52	Basic & Diluted EPS (Not Annualised)	36.52	37.89	36.52
-	22250000	-	18 Debt Equity Ratio	-	22250000	-
-	26.25	-	19 Debt Service Coverage Ratio	-	26.25	-
-	16.31	-	20 Interest Service Coverage Ratio	-	16.31	-
84753005	62503005	84753005	21 Public Shareholding	84753005	62503005	84753005
100.00	73.75	100.00	- Number of Shares	100.00	73.75	100.00
63.48	45.80	63.48	- Percentage of Shareholding	63.48	45.80	63.48
			22 Promoters and Promoter Group Shareholding			
			(a) Pledged / Encumbered			
			Number of Shares			
			Percentage of Shares (as a % of the total shareholding of promoter and promoter group)			
			Percentage of Shares (as a % of the total share capital of the Company)			
			(b) Non - Encumbered			
			Number of Shares			
			Percentage of Shares (as a % of the total shareholding of promoter and promoter group)			
			Percentage of Shares (as a % of the total share capital of the Company)			

Notes :

- 1 The above results, which includes unreviewed results of the Subsidiary, have been duly reviewed by Statutory Auditors, were recommended by the Audit Committee and were approved by Board of Directors.
- 2 The Company is engaged in Pharmaceutical business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Reporting (AS - 17)
- 3 The Board of Directors of the Company in its meeting held on 29th June, 2010 has approved scheme of arrangement containing demerger of its core pharmaceutical business into wholly owned subsidiary company viz. Alembic Pharma Limited. This scheme of arrangement is subject to approval from the Members, Stock Exchanges, other authorities and the Honorable High Court of Gujarat. The Bombay Stock Exchange and National Stock Exchange have given their NOC for the scheme of arrangement. The Company is now in process of getting necessary direction from the Hon'ble High Court of Gujarat to convene meetings of the members and creditors.
- 4 The Company has opted to publish consolidated financial results, pursuant to option made available as per clause 41 of the Listing Agreement. The Standalone Financial Results are available on the company's website viz. www.alembic-india.com and on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com).
- 5 Details of Investors' Complaints for the quarter ended on 30th June, 2010 : Unresolved at the beginning of the quarter-NIL Received during the quarter-8, Disposed off during the quarter-8 , Unresolved at the end of the quarter - NIL.
- 6 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

Place : Vadodara
Date : 30th July, 2010

Visit us at www.alembic-india.com

For Alembic Limited

Chirayu Amin
Chairman and Managing Director